Scott Hecker
@scottjhecker
Followers
12
Following
9
Media
0
Statuses
14
Joined July 2013
Want to see @IDWeek2022 of xeruborbactam head-to-head testing vs invest IV & oral beta-lactam/betaL-ase inhibs or activity vs DTR #AMR vs pathogens. TODAY: See posters 1692-3 by Olga Lomovskaya @mcastanheirajmi, & # 1736-7 by @IDPittStop Hong Nguyen, @ClancyNeil @ryankshields
0
3
1
Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid β-Lactamase Inhibitor QPX7728
pubs.acs.org
In recognition of the need for effective oral therapies to treat Gram-negative bacterial infections, efforts were directed toward identifying an oral prodrug of β-lactamase inhibitor clinical...
0
0
2
I miss #IDWeek2021 poster session discussions. Which oral beta-lactam antibiotic with QPX7728 looks most interesting vs resistant Enterobacterales? @gardp_amr @SIDPharm @CARB_X @AWG_News
@IDWeek2021: @mcastanheirajmi shows data on our beta-lactamase inhibitor QPX7728 delivered IV or PO restores the potency of multiple oral and IV beta-lactams vs R Enterobacteriales, including ESBL, KPC, OXA, & MBL strains. https://t.co/FMov0aRZoM
0
2
7
When I began my career in '80s, I practiced what is now called “antibiotic stewardship”– the right antibiotic to the right patient. But it was “patient stewardship.” We need to reform how best antibiotics are valued and reform how insurance pays for them. https://t.co/5hY4ZHg1fH
sandiegouniontribune.com
Dudley, doctor of pharmacy, is CEO of Qpex Biopharma. He lives in Escondido.I have a friend who was recently diagnosed with Stage 4 pancreatic cancer, with evidence of spread to the lungs and liver…
1
9
28
A scalable synthesis of β-lactamase inhibitor QPX7728 features a Ni-catalyzed boron insertion into a benzofuran followed by enantioselective cyclo-propanation with (+)-pseudoephedrine.
pubs.acs.org
We report the scalable, high-yielding, and highly selective synthesis of the β-lactamase inhibitor QPX7728 featuring two key synthetic steps: nickel-catalyzed boron insertion of benzofuran 1 followed...
0
1
4
Qpex Biopharma reports on an efficient process for manufacture of β-lactamase inhibitor QPX7728, featuring Ni-catalyzed boron insertion and enantioselective cyclopropanation
pubs.acs.org
We report the scalable, high-yielding, and highly selective synthesis of the β-lactamase inhibitor QPX7728 featuring two key synthetic steps: nickel-catalyzed boron insertion of benzofuran 1 followed...
0
0
2
Our CEO @MikeMndudley and SVP Olga Lomovskaya discuss #AMR and the pressing need for new and better antimicrobials – ones that address resistance of both class-specific and general-intrinsic mechanisms. Read more: https://t.co/hsUAgatPKo
0
1
2
ORAvance provides convenient oral delivery of QPX7728, our ultra-broad-spectrum beta-lactamase inhibitor that is also progressing in Phase 1 clinical trials in an IV form.
businesswire.com
Qpex Biopharma, Inc., (Qpex) a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, an...
0
0
1
Poster presentations (AAR-706 to 713) at #ASMicrobe on details of Qpex Biopharma’s ultra-broad-spectrum beta-lactamase inhibitor QPX7728 for IV and oral administration for #AMR on Sunday afternoon. #antimicrobials @AWG_News @SIDPharm
1
6
18
Wonder about a career discovering new antibiotics? Wonder why finding new classes of drugs for treatment of #AMR is hard, but how we did it? Come hear Qpex’s own Scott Hecker at #ASMicrobe Career Talk at POM Lounge and Learn at Moscone WEST (level 2) at 2:30pm Sunday.
0
2
5
QPX7728 in new agents summary now presented by our own Olga Lomovskaya
1
2
6
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections
1
13
38